News & Events

• September 20, 2023
  

  The CPP Consortium Welcomes Biohaven as its Newest Member

    The Critical Path for Parkinson’s Consortium is excited to welcome Biohaven as its newest member. Biohaven is a biopharmaceutical company aimed at discovering and developing novel life-changing therapies for people living with neurological and neuropsychiatric diseases by collaborating with leaders in scientific discovery and medicine. CPP is excited to work with Biohaven as one of many new members from......
• August 25, 2023
  

  C-Path is pleased to welcome Acurex Biosciences as the newest member joining its Critical Path for Parkinson’s Consortium

      AcureX is a pharmaceutical company on a mission to stop major neurodegenerative diseases before they start, with an initial focus on Parkinson’s disease. To achieve this, AcureX leverages a first-in-class peripheral drug-responsive biomarker assays to molecularly define and segment patients in combination with novel disease-modifying therapeutics. AcureX is ushering in a new era of precision medicine......
• January 23, 2023
  

  C-Path and Mobilise-D Collaborate to Improve Impact on the Organizations’ Common Goals

      Critical Path Institute is pleased to announce the recent collaboration agreement between C-Path and Mobilise-D. By combining C-Path’s unique global regulatory expertise and Mobilise-D’s focus on digital assessment of mobility, this mutually beneficial partnership aims to accelerate and improve the impact of these important initiatives that share common goals. The Critical Path for......
• March 28, 2022
  

  C-Path is proud to share our responses to the FDA draft guidance, Digital Health Technologies for Remote Data Acquisition in Clinical Investigations

  The Clinical Outcomes Assessment (COA), Critical Path for Parkinson’s Digital Drug Development (3DT) Initiative, and Type 1 Diabetes (T1D) Consortia all contributed to this effort, resulting in a combined set of comments on behalf of C-Path. By bringing together stakeholders across industry, regulatory agencies, patient groups, academic researchers and clinicians, disease foundations and other organizations......
• November 30, 2021
  

  Critical Path for Parkinson’s Shares Internship Highlights from Mikayla Spott

  Critical Path for Parkinson’s is proud to highlight Mikayla Spott who joined the team as CPP’s first consortium intern in August 2020. CPP was glad to play a part in her journey toward pursuing her dream of becoming a physician (and celebrates her recent acceptance to multiple medical schools!). “We are delighted to share her story and hope......